RxDoctor Payments DataLook up a doctor →

Todd Bender, NP

Nurse Practitioner · Lilburn, GANPI 1013360767

Payments from drug & device makers

$10,318in general payments, 2019–2025

Across 547 payments — averaging $18.86 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$2K
  • Amgen$727
  • AstraZeneca$615
  • GSK$584
  • Bayer$568
  • Pfizer$565
  • plus $5K from 45 others

What the payments were for

  • Food & beverage$10,318100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$10,318 in reported general payments places this provider in the 95th percentile of 3,328 nurse practitioner providers in Georgia.

See all nurse practitioner providers in Georgia

Medicare billing

Part B allowed, 2024
$8,859
Medicare patients
40
Services billed
164

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
FarxigaDapagliflozin Propanediol57$58,762
EliquisApixaban51$55,486
Trelegy ElliptaFluticasone/Umeclidin/Vilanter57$48,757
XareltoRivaroxaban27$29,815
OzempicSemaglutide21$28,076
GemtesaVibegron17$20,941
MounjaroTirzepatide16$20,410
TrulicityDulaglutide14$19,641
JardianceEmpagliflozin18$17,560
VraylarCariprazine Hcl12$17,030
KerendiaFinerenone17$15,193
MyrbetriqMirabegron19$13,838
ShingrixVaricella-Zoster Ge/As01b/Pf23$5,104
Albuterol Sulfate HfaAlbuterol Sulfate107$3,202
Adacel TdapDiph,pertuss(Acell),tet Vac/Pf33$2,292

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaFarxiga$615$58,76257 claims
PfizerEliquis$565$55,48651 claims
GSKTrelegy Ellipta, Shingrix$584$53,86080 claims
Lilly USA, LLCMounjaro, Trulicity$508$40,05130 claims
Johnson & JohnsonXarelto$507$29,81527 claims
Novo NordiskOzempic$257$28,07621 claims
Sumitomo Pharma America, Inc.Gemtesa$334$20,94117 claims
AbbVieVraylar, Synthroid$2,089$18,56539 claims
Boehringer IngelheimJardiance$150$17,56018 claims
BayerKerendia$568$15,19317 claims
Astellas Pharma US IncMyrbetriq$356$13,83819 claims
Amneal Pharmaceuticals LLCLevothyroxine Sodium$59$938108 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 3,328 nurse practitioner providers in Georgia.

Other nurse practitioner in Lilburn

See the full list for Georgia

Where these figures come from

Is this you, or does something look wrong? →